Dobberfuhl, Amy D. http://orcid.org/0000-0003-3451-3878
van Uem, Stefanie http://orcid.org/0000-0003-4484-5489
Versi, Eboo http://orcid.org/0000-0001-9366-7370
Funding for this research was provided by:
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Foundation (SUFU Foundation Study of Chemodenervation)
National Institutes of Health (NIH 1L30DK115056-01)
The Stanford Women’s Health and Sex Differences in Medicine (Seed Grant for Biological/Medical Research on Sex Differences and/or Women’s Health)
Article History
Received: 17 March 2021
Accepted: 20 May 2021
First Online: 22 June 2021
Declarations
:
: A. Dobberfuhl is an investigator for the SUFU Foundation seed grant entitled “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder.” S. van Uem declares no conflicts of interest in relation to the content of the manuscript. E. Versi is the inventor of patent USPTO #8,029,496 entitled “Method and device for delivering drug to the trigone of the bladder” and consultant for Hologic Inc.